secwatch.observer — SEC 8-K summary
======================================

Issuer:     CERUS CORP (CERS)
CIK:        0001020214
Form:       8-K
Filed at:   2021-11-02T23:59:59+00:00
Accession:  0001193125-21-316919
Event type: earnings
Sentiment:  positive
Materiality: 0.80
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Cerus Q3 product revenue $36.1M (+53% YoY); raises FY21 guidance to $127-129M
-----------------------------------------------------------------------------

- Total revenue $42.1M (+44% YoY); product revenue $36.1M (+53% YoY) driven by U.S. INTERCEPT platelet adoption.
- Net loss $12.4M ($0.07/shr) improved from $14.1M ($0.08/shr) in Q3 2020.
- Product gross margin 51.3% vs 53.6% YoY; gross profit record $18.5M.
- FY21 product revenue guidance raised to $127-129M (from $118-122M), representing 38-40% growth.
- Cash and short-term investments $120.0M at Sept 30; $55M notes due, $10M revolver drawn.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1020214/000119312521316919/0001193125-21-316919-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1020214/000119312521316919/d220853d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-21-316919

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer